Skip to content

‘Do patients benefit from an Attentional Avoidance Training during an inpatient alcohol detoxification?’

What is the best timing to offer Attentional Avoidance Training to patients?

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
NL-OMON
Registry ID
NL-OMON28545
Enrollment
240
Registered
2021-04-26
Start date
2021-04-26
Completion date
Unknown
Last updated
2024-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

alcohol use disorder

Interventions

Sponsors

does not apply
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: In order to be eligible to participate in this study, a subject must meet all of the following criteria: - Informed consent - 18 years or older - meet the Diagnostic and Statistical Manual-5 criteria for alcohol use disorder (AUD, American Psychiatric Association, 2013) - medical indication for inpatient alcohol detoxification treatment

Exclusion criteria

Exclusion criteria: A potential subject who meets any of the following criteria will be excluded from participation in this study, if there is any medical or psychiatric disorder or deficit in Dutch language proficiency that prohibits a good understanding of questions and instructions or the ability to take part in the AAT. Patients with a severe neurological disorder such as Korsakoff syndrome will be excluded.

Design outcomes

Primary

MeasureTime frame
The aim of the present study is to assess the effectiveness of an Alcohol Avoidance Training (AAT) and if the timing of the training is distinctive when applied during or after an inpatient detoxification.

Secondary

MeasureTime frame
Secondary outcome variables are the alcohol abstinence at three and six months post training, and alcohol craving rate and psychological complaints at two weeks, three and six months post training. Additionally, the expectations and evaluation (acceptability and feasibility) of the Alcohol AAT will be assessed.

Contacts

Public ContactNicolle van Mil

Novadic-Kentron

nicolle.van.mil@novadic-kentron.nl0612035572

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)